GlucoVera (Glimepiride) is an oral blood-glucose-lowering drug of the sulfonylurea
Glimepiride is an anti-diabetic drug used along with a proper diet and exercise
program to control high blood sugar. It is used in patients with type 2 diabetes
(non-insulin-dependent diabetes). It works by stimulating the release of your body's
natural insulin. Controlling high blood sugar helps prevent kidney damage, blindness,
nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes
may also lessen your risk of a heart attack or stroke.
How to Use
Take this medication by mouth usually once daily, with breakfast or the first main
meal of the day. The dosage is based on your medical condition and response to therapy.
Use this medication regularly in order to get the most benefit from it. To help
you remember, use it at the same time each day. Monitor blood glucose levels on
a regular basis, and share the results with your doctor.
GlucoVera must not be used in:
1. Patients with known hypersensitivity to glimepiride.
2. Patients with Insulin Dependent (Type I) Diabetes.
3. Diabetic Ketoacidosis with or without coma (this condition should be treated
4. Pregnancy, nursing mothers or in children.
1. Eye: especially at the start of treatment, temporary visual
impairment may occur due to the change in blood sugar level.
2. Gastrointestinal: nausea, vomiting, abdominal pain and diarrhea.
3. Hematologic reactions: leucopenia, agranulocytosis, thrombocytopenia,hemolytic
anemia, aplastic anemia and pancytopenia.
4. Metabolic reactions: hepatic porphyria and disulfiram like reactions
All sulfonylurea drugs are capable of producing severe hypoglycemia. Proper patient
selection, dosage, and instructions are important to avoid hypoglycemic episodes.
Patients with impaired renal function may be more sensitive to the glucose-lowering
effect of GlucoVera. A starting dose of 1 mg once daily followed by appropriate
dose titration is recommended in those patients. Debilitated or malnourished patients,
and those with adrenal, pituitary, or hepatic insufficiency are particularly susceptible
to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult
to recognize in patients with autonomic neuropathy, the elderly and in people who
are taking beta-adrenergic blocking drugs or other sympatholytic agents. Hypoglycemia
is more likely to occur when caloric intake is deficient, after severe or prolonged
exercise, when alcohol is ingested, or when more than one glucose-lowering drug
is used. Combined use of glimepiride with insulin or metformin may increase the
potential for hypoglycemia.
Symptoms of high blood sugar (hyperglycemia) include thirst, increased urination,
confusion, drowsiness, flushing, rapid breathing, or fruity breath odor. If these
symptoms occur, tell your doctor immediately. Your medication dosage may need to
A serious allergic reaction to this drug is unlikely, but seek immediate medical
attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling
(especially of the face/tongue/throat), dizziness, trouble breathing.
Treatment of patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency with
sulfonylurea agents can lead to hemolytic anemia. Since GlucoVera belongs to the
class of sulfonylurea agents, caution should be used in patients with G6PD deficiency
and a non-sulfonylurea alternative should be considered. In postmarketing reports,
hemolytic anemia has been reported in patients who did not have known G6PD deficiency.
This is not a complete list of possible side effects. If you notice other effects
not listed above, contact your doctor.
Overdosage of sulfonylureas (GlucoVera), can produce hypoglycemia. Mild hypoglycemic
symptoms without loss of consciousness or neurologic findings should be treated
aggressively with oral glucose and adjustments in drug dosage and/or meal patterns.
Close monitoring should continue until the physician is assured that the patient
is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological
impairment occur infrequently, but constitute medical emergencies requiring immediate
hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should
be given a rapid intravenous injection of concentrated (50%) glucose solution. This
should be followed by a continuous infusion of a more dilute (10%) glucose solution
at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients
should be closely monitored for a minimum of 24 to 48 hours, because hypoglycemia
may recur after apparent clinical recovery.
If a dose is missed, take it as soon as got remind. If the time of the next dose
is near then skip the missed dose and follow the usual dosing schedule. Do not double
the dose to catch up.
Glimepiride (GlucoVera) is an oral diabetes medicine that helps control blood sugar
levels. This medication helps your body respond better to insulin produced by your
Glimepiride (GlucoVera) is used together with diet and exercise to treat type 2
(non-insulin dependent) diabetes. Insulin or other diabetes medicines are sometimes
used in combination with glimepiride if needed.
Get emergency medical help if you have any of these signs of an allergic reaction:
hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
1. seere skin rash, itching, redness, or irritation.
2. pale skin, easy bruising or bleeding, fever, unusual weakness.
3. dark urine, clay-colored stools.
4. upper stomach pain, low fever, jaundice (yellowing of the skin or eyes) or nausea,
vomiting, loss of appetite, feeling restless or irritable, confusion, hallucinations,
muscle pain or weakness, and/or seizure.
Less serious side effects may include:
1. dizziness, headache, tired feeling.
2. mild nausea, vomiting, stomach pain, diarrhea.
3. increased skin sensitivity to sunlight or mild itching or skin rash.
Know the signs of low blood sugar (hypoglycemia) and how to recognize them. Always
keep a source of sugar available in case you have symptoms of low blood sugar. Sugar
sources include orange juice, glucose gel, candy, or milk. Severe hypoglycemia may
cause loss of consciousness, seizures, or death. If you have severe hypoglycemia
and cannot eat or drink, give an injection of glucagon. Your doctor can give you
a prescription for a glucagon emergency injection kit and tell you how to give the
If your blood sugar gets too high (hyperglycemia), you may feel very thirsty or
hungry. You may also urinate more than usual. Call your doctor right away if you
have any symptoms of hyperglycemia.
This is not a complete list of side effects and others may occur. Call your doctor
for medical advice about side effects.
Do not use this medication if you are allergic to glimepiride, or if you are in
a state of diabetic ketoacidosis (call your doctor for treatment with insulin).
Take care not to let your blood sugar get too low, which can be caused by stress,
skipping a meal, exercising too long, or drinking alcohol.
Glimepiride is only part of a complete program of treatment that also includes diet,
exercise, and weight control. Follow your diet, medication, and exercise routines
very closely. Changing any of these factors can affect your blood sugar levels.
You should not use this medication if you are allergic to glimepiride, or if you
are in a state of diabetic ketoacidosis (call your doctor for treatment with insulin).
If you have certain conditions, you may need a dose adjustment or special tests
to safely take this medication. Before you take glimepiride, tell your doctor if
1. heart disease
2. liver or kidney disease
3. an enzyme deficiency called glucose-6-phosphate dehydrogenase deficiency (G6PD)
4. adrenal or pituitary gland problems or if you are under-nourished.
FDA pregnancy category C. It is not known whether glimepiride is harmful to an unborn
baby. Before using glimepiride, tell your doctor if you are pregnant or plan to
become pregnant during treatment.
It is not known whether glimepiride passes into breast milk or if it could be harmful
to a nursing baby. Do not take glimepiride without telling your doctor if you are
breast-feeding a baby
Take glimepiride exactly as it was prescribed for you. Do not take the medication
in larger or smaller amounts, or take it for longer than recommended by your doctor.
Follow the directions on your prescription label.
Your dose needs may change if you are ill, if you have a fever or infection, or
if you have surgery or a medical emergency.
Do not change your dose of glimepiride without first talking to your doctor.
Glimepiride is usually taken once a day with breakfast or the first main meal of
the day. Follow your doctor's instructions. Take glimepiride with a full glass of
Store glimepiride at room temperature away from moisture and heat.
Take the missed dose as soon as you remember. If it is almost time for your next
dose, wait until then to take the medicine and skip the missed dose. Do not take
extra medicine to make up the missed dose.
Seek emergency medical attention if you think you have used too much of this medicine.
A glimepiride overdose can cause life-threatening hypoglycemia.
Symptoms of severe hypoglycemia include extreme weakness, blurred vision, sweating,
trouble speaking, tremors, stomach pain, confusion, seizure (convulsions), and coma.
Avoid drinking alcohol. It lowers blood sugar and may interfere with your diabetes
Avoid exposure to sunlight, sunlamps, or tanning beds. Glimepiride can make your
skin more sensitive to sunlight, and a sunburn may result. Wear protective clothing
and use sunscreen (SPF 15 or higher) when you are outdoors.
Using certain medicines can make it harder for you to tell when you have low blood
sugar. Tell your doctor if you use any of the following:
5. A beta-blocker such as atenolol, carvedilol, labetalol, metoprolol, nadolol,
propranolol, sotalol, and others.
You may be more likely to have hypoglycemia (low blood sugar) if you are taking
glimepiride other drugs that lower blood sugar. Drugs that can lower blood sugar
3. Some nonsteroidal anti-inflammatory drugs (NSAIDs)
4. Aspirin or other salicylates
5. A blood thinner (warfarin, Coumadin and others).
6. A monoamine oxidase inhibitor (MAOI).
7. Sulfa drugs.
You may be more likely to have hyperglycemia (high blood sugar) if you are taking
glimepiride with other drugs that raise blood sugar. Drugs that can raise blood
2. Diuretics (water pills)
3. Steroids (prednisone and others)
5. Thyroid medicine.
6. Birth control pills and other hormones.
7. Seizure medicines.
8. Diet pills.
9. Medicines to treat asthma, colds or allergies.
These lists are not complete and there are many other medicines that can increase
or decrease the effects of glimepiride on lowering your blood sugar. Tell your doctor
about all the prescription and over-the-counter medications you use. This includes
vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not
start using a new medication without telling your doctor. Keep a list with you of
all the medicines you use and show this list to any doctor or other healthcare provider
who treats you.
Your pharmacist can provide more information about Glimepiride. And you can contact
us at firstname.lastname@example.org
Remember, keep this and all other medicines out of the reach of children, never
share your medicines with others, and use this medication only for the indication
GlucoVera 1 mg tabletsPink color oblong biplanar shaped tablet engraved B/H on one side other side plain with score line.
GlucoVera 2 mg tabletsGreen color oblong biplanar shaped tablet engraved B/H on one side, other side plain with score line
GlucoVera 3 mg tabletsYellow color oblong biplanar shaped tablet engraved B/H on one side, other side plain with score line
GlucoVera 4 mg tabletsBlue color oblong biplanar shaped tablet engraved B/H on one side, other side plain with score line
Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: results of a
1.5-year follow-up study
Raimund Weitgassera, Monika Lechleitnerb, Anton Lugerc, Anton Klinglerd
Received 26 February 2002; received in revised form 7 November 2002; accepted 11
Sulphonylureas are effective and well tolerated in patients with Type 2 diabetes,
but may be associated with weight gain, and lack of compliance due to multiple daily
dosing. This open, uncontrolled surveillance study examined the efficacy and safety
of glimepiride, a new sulphonylurea, administered once daily in patients with Type
2 diabetes. A total of 1770 patients were enrolled in the study, and 284 patients
were selected for follow-up. Patients received 0.5 to >4 mg glimepiride once
daily for 1.5 years. HbA1c was reduced from 8.4% at baseline to 7.1% after 4 months
and 6.9% after 1 and 1.5 years (median intra-individual change from baseline: −1.4,
−1.5, and −1.7%, respectively; P<0.0001). Treatment with glimepiride
also resulted in significant and stable weight loss relative to baseline, with the
exception of patients with a body mass index of <25 kg/m2.Mean body
weight was reduced from 79.8 kg at baseline to 77.9 kg after 4 months, 77.2 kg after
1 year, and 76.9 kg after 1.5 years (mean intra-individual change from baseline:
−1.9 kg, P<0.0001; −2.9 kg, P<0.05; −3.0 kg, P<0.005,
respectively). Therefore, once daily glimepiride provides effective glycaemic control,
and may have advantages over other sulphonylureas, because it exhibits weight neutralizing/reducing
effects in patients with Type 2 diabetes.
Volume 61, Issue 1, Pages 13-19 (July 2003)
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in
patients with newly diagnosed type 2 diabetes mellitus
Dan-yan Xua, Shui-Ping Zhaoa, Qiu-xia Huangb, Wei Dub, Yu-hua Liub, Ling Liua, Xiao-mei
Received 20 September 2007; received in revised form 10 July 2009; accepted 8 December
2009. published online 04 January 2010.
To investigate the effects of Glimepiride on blood glucose in patients with newly
diagnosed type 2 diabetes mellitus (T2DM) in connection with plasma lipoproteins
and plasminogen activity.
A total of 565 T2DM patients were received Glimepiride (n = 333) or Glibenclamide
(n = 232) for 12 weeks. We observed the level of blood glucose (BG), glycated hemoglobin
(HbA1C), the insulin resistance (IR) state, plasma lipoproteins, tissue-type plasminogen
activator (t-PA) and plasminogen activator inhibitor type I (PAI-1) before and after
a 12 weeks of treatment.
After 12 weeks with Glimepiride treatment, significant reductions were observed
in fasting blood glucose (FBG) and 2-h postprandial BG(PBG), HbA1C (from 8.60 ±
3.10 to 7.10 ± 1.60%) and HOMA-IR (from 4.11 ± 0.85 to 2.42 ±
0.91%). The level of total cholesterol (TC), triglyceride (TG), and low-density
lipoprotein cholesterol (LDL-C) were significantly decreased, whereas that of high-density
lipoprotein (HDL) was increased markedly with statistical significance. In addition,
there was an obvious improvement in t-PA activity (from 0.225 ± 0.11 to 0.457
± 0.177 IU/ml); whereas the PAI-1 activity was decreased significantly (from
0.898 ± 0.168 to 0.533 ± 0.215 AU/ml). No significant changes were
observed in plasma lipoprotein profiles and plasminogen activity in Glibenclamide
Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism,
significantly alleviate insulin resistance and enhance fibrinolytic activity.
Volume 88, Issue 1, Pages 71-75 (April 2010)
Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide
Tomoya Hamaguchiab, Takahisa Hirosea, Hideki Asakawaa, Yoshiharu Itoha, Keiji Kamadoa,
Katsuto Tokunagaa, Koji Tomitaa, Hiroshi Masudaa, Nobuaki Watanabea, Mitsuyoshi
Received 4 November 2003; accepted 2 December 2003. published online 26 August 2004.
Multicentric study was conducted to evaluate the efficacy of glimepiride in the
oral hypoglycemic agents therapy of type 2 diabetic patients treated with glibenclamide
so far, and to claim an adequate use of this new generation sulfonylurea. In 66
diabetic outpatients, glibenclamide was switched to glimepiride. After 6 months’
therapy, a significant reduction in fasting plasma IRI was observed in relatively
hyperinsulinemic patients. In addition, weight reduction was achieved in patients
with insulin resistance during this study. These findings suggest that glimepiride
improves insulin resistance in hyperinsulinemic patients treated with glibenclamide.
Also, glimepiride is favored especially for overweight, insulin-resistant patients
inadequately controlled by glibenclamide.
Volume 66, Supplement, Pages S129-S132 (December 2004)
Glimerpiride in type 2 diabetes mellitus: A review of the worldwide therapeutic
experience Massimo Massi-Benedetti MD
Dan-yan Xua, Shui-Ping Zhaoa, Qiu-xia Huangb, Wei Dub, Yu-hua Liub, Ling Liua, Xiao-mei
Dipartimento di Medicina Interna, Università di Perugia, Perugia, Italy
Accepted 6 December 2002.
Available online 7 July 2003.
Sulfonylureas (SUs) have been used for many years as first-line therapy for patients
with type 2 diabetes mellitus whose blood glucose levels have not been effectively
controlled by diet and exercise alone. Glimepiride is a once-daily SU that was introduced
in 1995. Since then, a considerable body of evidence has been amassed regarding
its use in type 2 diabetes.
This review provides a comprehensive summary of available data on the pharmacology,
pharmacokinetics, efficacy, and safety profile of glimepiride in the treatment of
type 2 diabetes. It also examines the use of glimepiride to achieve and maintain
good glycemic control in patients with type 2 diabetes in current clinical practice.
Relevant articles were identified through a search of MEDLINE for English-language
studies published from 1990 to 2002. The search terms used were glimepiride, sulfonylureas,
and type 2 diabetes mellitus. The manufacturer of glimepiride provided additional
Glimepiride differs from other SUs in a number of respects. In clinical studies,
glimepiride was generally associated with a lower risk of hypoglycemia and less
weight gain than other SUs. Results of other studies suggest that glimepiride can
be used in older patients and those with renal compromise. There is evidence that
glimepiride preserves myocardial preconditioning, a protective mechanism that limits
damage in the event of an ischemic event. Glimepiride can be used in combination
with other oral antidiabetic agents or insulin to optimize glycemic control.
Based on the evidence to date, glimepiride is an effective and well-tolerated once-daily
antidiabetic drug and provides an important treatment option for the management
of type 2 diabetes.
Volume 25, Issue 3, March 2003, Pages 799-816